Physician profile
Amylie A Rojas
NPI 1104489475
$1,073.38
in general payments reported to CMS, 2019-2025
15 companies · $54.36 in 2025
The $54.36 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $94.79 · 2023: $411 · 2024: $514 · 2025: $54.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $978.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $372.58 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $169.66 | 2022-2024 | Ozempic, Rybelsus |
| Pfizer INC. | $88.85 | 2023-2024 | |
| Lilly USA, LLC | $70.52 | 2024 | Zepbound, Jardiance, Mounjaro |
| Sumitomo Pharma America, INC. | $61.11 | 2023 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.12 | 2022-2025 | Jardiance |
| Sanofi Pasteur INC. | $48.94 | 2023-2024 | |
| Sunovion Pharmaceuticals INC. | $44.43 | 2022 | |
| Dynavax Technologies Corporation | $37.77 | 2022-2024 | Heplisav-B |
| Glaxosmithkline, LLC. | $34.97 | 2023-2025 | Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $20.73 | 2023 | Dificid |
| Otsuka America Pharmaceutical, INC. | $19.36 | 2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $18.01 | 2023 | Xarelto |
| Dexcom, INC. | $16.72 | 2024 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals Lp | $13.61 | 2024 | Airsupra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amylie Rojas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.